Skip to main content
Premium Trial:

Request an Annual Quote

Wash U. to Add 21 Illumina Genome Analyzers to Stockpile

NEW YORK (GenomeWeb News) - Washington University plans to buy 21 of Illumina's Genome Analyzers in the coming months that it will use in its human genomics programs.

The company said today that it has an agreement in principle with the university that, when complete, will provide the Genome Center at Washington University's School of Medicine in St. Louis with a total of 35 of its GA systems. With the additional sequencing capacity, and after "continued improvements" are made to the system, the center will be able to sequence one human genome per day at 25x coverage, the company said.

The center currently is participating in the National Institutes of Health's Cancer Genome Atlas program and the 1000 Genomes Project.

"Our intention to substantially scale-up with this technology reflects our commitment to large-scale sequencing projects that aim to uncover the underlying genetic basis of various human diseases," Richard Wilson, director of the Genome Center, said in a statement. "With the rapid decline in the cost of whole-genome sequencing, we believe now is the time to embark on initiatives which were previously not possible."

Financial terms of the agreement were not released.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.